BJMO - volume 17, issue 4, june 2023
A. Verbiest MD, PhD, M. Baldewijns MD, PhD, B. Beuselinck MD, PhD, P. Debruyne MD, PhD, C. Gennigens MD, PhD, G. Pelgrims MD, T. Roumeguère MD, PhD, E. Seront MD, PhD, N. Sundahl MD, PhD, S. Rottey MD, PhD
The management of renal cell carcinoma is evolving rapidly. Here, the BSMO expert panel discusses recent advances focusing on systemic therapies, and provides guidelines adapted to the Belgian context.
(BELG J MED ONCOL 2023;17(4):118–27)
Read moreBJMO - volume 14, issue 2, march 2020
B. Delafontaine MD, C. De Backer MD, B. Beuselinck MD, PhD, P. Debruyne MD, PhD, L. D’Hondt MD, PhD, C. Gennigens MD, PhD, T. Gil MD, C. Vulsteke MD, PhD, N. Martínez Chanzá MD, A. Verbiest MD, PhD, M. Strijbos MD, PhD, G. Van Lancker MD, G. Pelgrims MD, S. Rottey MD, PhD, On behalf of the BSMO Uro-Oncology Task Force Group
The management of recurrent or metastatic renal cell carcinoma is evolving fast, with new therapeutic options becoming available that may improve the outcome of patients. In this paper, recent evolutions are discussed and recommendations are made regarding the management of renal cell carcinoma in a Belgian context.
(BELG J MED ONCOL 2020;14(2):56–70)
Read moreBJMO - volume 13, issue 7, november 2019
C. Soenens MD, G. De Meerleer MD, PhD, M. Albersen MD, PhD, H. Van Poppel MD, PhD, B. Beuselinck MD, PhD
Based on a case report of a 47-year old male with primary bone metastatic renal cell carcinoma, the current treatment options are reviewed in this article.
(BELG J MED ONCOL 2019;13(7):305–8)
Read moreBJMO - 2017, issue 3, february 2017
A. Verbiest MD, PhD, J. Zucman-Rossi , D. Lambrechts PhD, B. Beuselinck MD, PhD
BJMO - 2017, issue 3, february 2017
T. Loyson , T. Van Cann , C. Politis , B. Beuselinck MD, PhD
BJMO - 2017, issue 3, february 2017
T. Van Cann , T. Loyson , C. Politis , P. Debruyne MD, PhD, B. Beuselinck MD, PhD
BJMO - volume 9, issue 1, february 2015
B. Beuselinck MD, PhD
Several years after approval of anti-vascular endothelial growth factor-targeted therapy for locally advanced and metastatic clear cell renal cell carcinoma, we discovered and/or validated new clinical, biochemical, pathological, pharmacokinetic, molecular and genetic markers predictive for response and/or prognostic in metastatic clear cell renal cell carcinoma patients treated with anti-vascular endothelial growth factor-receptor-tyrosine kinase inhibitors.
(BELG J MED ONCOL 2015;9(1):35–41)
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
